News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Stem cell therapies are on the brink of breaking through into the mainstream drug market, according to a GlobalData report, despite having been hindered by a lack of R&D funding.
Peregrine Pharmaceuticals is expanding its contract manufacturing capacity to meet growing client demand and to produce its own monoclonal antibody bavituximab, the company has revealed.
Pierre Fabre has spared its biopharmaceutical research team from job cuts unveiled last night, signalling that high value biologics will be a focus for its reduced pharma R&D activities.